TerminatedNCT00767715
A Study in the Treatment of Acute Mania
Medication studyAges 18–60SwedenBipolarity
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- DanderydSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateOctober 2004
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 11
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Sweden
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00767715
- Official title
Show the full official title
A Randomized Open Label Study on the Efficacy, Tolerability, and Total Costs of Olanzapine Versus Conventional Antipsychotics in the Treatment of Acute Mania in Sweden
Recruitment & locations
TerminatedDanderyd
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including olanzapine, haloperidol and zuclopentixol.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
Add-on treatment of mental illness with anti-viral medicine
Efficacy and Safety of Lu AA34893 in Patients With Depression in bipolarity